(2026). MRI and 18F-fluorothymidine PET-MR for the early evaluation of renal and bone marrow effects in 177Lu-DOTATATE therapy. Endocrine Oncology.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"MRI and 18F-fluorothymidine PET-MR for the Early Evaluation of Renal and Bone Marrow Effects in 177Lu-DOTATATE Therapy."
Endocrine Oncology 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"MRI and 18F-fluorothymidine PET-MR for the Early Evaluation of Renal and Bone Marrow Effects in 177Lu-DOTATATE Therapy."
Endocrine Oncology, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.